These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18083382)

  • 1. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
    [No Abstract]   [Full Text] [Related]  

  • 2. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 3. Judge strikes down FDA policies on industry dissemination of off-label information.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1695-6. PubMed ID: 10512492
    [No Abstract]   [Full Text] [Related]  

  • 4. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 5. Rules set for dissemination of off-label-use information.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of pharmacoeconomics and outcomes research.
    Radensky P
    Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 9. What drug labels don't tell you.
    Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
    [No Abstract]   [Full Text] [Related]  

  • 10. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 12. Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
    Kalb PE; Greenberg PE
    Pharmacoeconomics; 2009; 27(8):623-5. PubMed ID: 19835018
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 15. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 18. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA scrutinizes 'off-label' promotions.
    Randall T
    JAMA; 1991 Jul; 266(1):11. PubMed ID: 2046119
    [No Abstract]   [Full Text] [Related]  

  • 20. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.